Sexist comments common at JP Morgan Healthcare Conference

Gender equality at the JP Morgan Healthcare Conference in San Francisco had already appeared to be an issue when it was reported by STAT that more men named Michael were presenting at the event than all women combined. Another STAT story says the problems go deeper in the “party culture” surrounding the show.

The conference “is sort of a mosh pit of power and insecurity — along with sleeplessness and excessive consumption of alcohol. Those four factors are never good, especially in combination … it’s a bit of a recipe for disaster,” said Nina Kjellson, a general partner at the venture capital firm Canaan.

Women told STAT male attendees had made comments towards them such as “I can’t believe you’re so smart and you’re so attractive,” or questioning why a female CEO wasn’t “at home raising your kids” instead of pitching to male venture capitalists.

While female attendees said their experiences at the conference have also been valuable and enjoyable, many also described it as a “boys club,” and have informally advised each other on how to navigate the event. Among their tips: Stay focused on your work and if you go out drinking at night, always have a trusted friend with you.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.